95 related articles for article (PubMed ID: 11492990)
21. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure.
De Tommasi E; Iacoviello M; Romito R; Ceconi C; Guida P; Massari F; Francolini G; Bertocchi F; Ferrari R; Rizzon P; Pitzalis MV
Am Heart J; 2003 Nov; 146(5):E17. PubMed ID: 14597946
[TBL] [Abstract][Full Text] [Related]
22. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
24. Lisinopril: a review of its use in congestive heart failure.
Simpson K; Jarvis B
Drugs; 2000 May; 59(5):1149-67. PubMed ID: 10852646
[TBL] [Abstract][Full Text] [Related]
25. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
Einhorn PT; Davis BR; Massie BM; Cushman WC; Piller LB; Simpson LM; Levy D; Nwachuku CE; Black HR;
Am Heart J; 2007 Jan; 153(1):42-53. PubMed ID: 17174636
[TBL] [Abstract][Full Text] [Related]
26. [The ATLAS study (Assessment of Treatment with Lisinopril and Survival); justification and objectives].
Komajda M; Wimart MC; Thibout E
Arch Mal Coeur Vaiss; 1994 Jun; 87 Spec No 2():45-50. PubMed ID: 7864722
[TBL] [Abstract][Full Text] [Related]
27. Antiarrhythmic therapy in heart failure.
Eckardt L; Haverkamp W; Breithardt G
Heart Fail Monit; 2002; 2(4):110-9. PubMed ID: 12634885
[TBL] [Abstract][Full Text] [Related]
28. The HOPE Study (Heart Outcomes Prevention Evaluation).
Sleight P
J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
[TBL] [Abstract][Full Text] [Related]
29. [Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic].
Pölzl G; Gouya G; Hügel H; Frick M; Ulmer H; Pachinger O
Wien Klin Wochenschr; 2002 Oct; 114(19-20):833-9. PubMed ID: 12503474
[TBL] [Abstract][Full Text] [Related]
30. Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study.
Cleland JG; Armstrong P; Horowitz JD; Massie B; Packer M; Poole-Wilson PA; Rydén L
Eur J Heart Fail; 1999 Mar; 1(1):73-9. PubMed ID: 10937983
[TBL] [Abstract][Full Text] [Related]
31. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
[TBL] [Abstract][Full Text] [Related]
32. [Clinical study of the month. The ATLAS study].
Kulbertus H
Rev Med Liege; 1999 Dec; 54(12):952-4. PubMed ID: 10686803
[TBL] [Abstract][Full Text] [Related]
33. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Treatment with Lisinopril and Survival ATLAS study.
Int J Clin Pract Suppl; 1999 Apr; 100():24. PubMed ID: 10658297
[No Abstract] [Full Text] [Related]
35. ATLAS: high dose lisinopril is superior to low dose in heart failure.
Jackson G
Int J Clin Pract; 1998; 52(3):139. PubMed ID: 9684425
[No Abstract] [Full Text] [Related]
36. High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial.
Schwartz JS; Wang YR; Cleland JG; Gao L; Weiner M; Poole-Wilson PA;
Am J Manag Care; 2003 Jun; 9(6):417-24. PubMed ID: 12816171
[TBL] [Abstract][Full Text] [Related]
37. Results of the ATLAS study.
Rydén L
Int J Clin Pract Suppl; 1999 Apr; 100():17-8. PubMed ID: 10658294
[No Abstract] [Full Text] [Related]
38. High dose lisinopril in heart failure: economic considerations.
Ess SM; Lüscher TF; Szucs TD
Cardiovasc Drugs Ther; 2002 Jul; 16(4):365-71. PubMed ID: 12652106
[TBL] [Abstract][Full Text] [Related]
39. Implications of the ATLAS study for clinical practice.
Packer M
Int J Clin Pract Suppl; 1999 Apr; 100():21-3. PubMed ID: 10658296
[No Abstract] [Full Text] [Related]
40. Heart failure management in primary care: implications of the ATLAS study.
Int J Clin Pract Suppl; 1999 Apr; 100():25-30. PubMed ID: 10658298
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
